Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocon Settles with Janssen to Commercialise Biosimilar Products in Europe, Canada, Japan
Details : The agreement aims to commercialize its Bmab 1200, a proposed biosimilar to Stelara and a monoclonal antibody medication, in Europe, the United Kingdom (UK), Canada, and Japan.
Brand Name : Bmab 1200
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 29, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biocon Biologics gets FDA nod for Yesafili™, enters U.S. ophthalmology market
Details : Yesafili (aflibercept) is a PGF & VEGF-A inhibitor, its single-dose vial formulation is approved for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.
Brand Name : Yesafili
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 21, 2024
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Eris Pharmaceuticals
Deal Size : $150.0 million
Deal Type : Collaboration
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln
Details : The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.
Brand Name : ACTIBLOK IPR 25
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 13, 2024
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Eris Pharmaceuticals
Deal Size : $150.0 million
Deal Type : Collaboration
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Partnership
Biocon Biologics Partners with Sandoz for Biosimilars
Details : The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar utilized in patients diagnosed with breast cancer or metastatic stomach cancer.
Brand Name : Ogivri
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 10, 2024
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Everolimus
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Eris Lifesciences
Deal Size : $43.8 million
Deal Type : Divestment
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations
Details : Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Brand Name : Advacan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Everolimus
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Eris Lifesciences
Deal Size : $43.8 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?